1. Show article details.

    Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 03/17/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted a stock option to purchase 151,200 shares of Karyopharm’s common stock to John Demaree, the Company’s newly-appointed Chief Commercial Officer, with a grant date of March 16, 2020.

  2. Show article details.

    Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer

    GlobeNewswire – 7:00 AM ET 03/12/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced the appointment of John Demaree as Chief Commercial Officer.

  3. Show article details.

    Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 03/09/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 119,500 shares of Karyopharm’s common stock to seventeen newly-hired employees, with a grant date of March 5, 2020.

  4. Show article details.

    Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

    GlobeNewswire – 4:05 PM ET 03/06/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced the closing of its previously announced registered underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares. J.P. Morgan, Morgan Stanley and Jefferies acted as joint book-running managers for the offering.

  5. Show article details.

    Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 6:36 PM ET 03/03/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced the pricing of its previously announced registered underwritten public offering of 6,250,000 shares of its common stock  at a price to the public of $24.00 per share.

  6. Show article details.

    Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 03/02/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced the commencement of a registered underwritten public offering of $150 million in shares of its common stock. J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering.

  7. Show article details.

    Karyopharm's stock jumps on trial results for multiple myeloma combo candidate

    MarketWatch – 12:57 PM ET 03/02/2020

    Shares of Karyopharm Therapeutics Inc. (KPTI) soared 65% in trading on Monday after the drugmaker said an experimental combination treatment for multiple myeloma met its primary endpoint in a late-stage clinical trial. The combination pairs Karyopharm's Xpovio, which received Food and Drug Administration approval in mid-2019, with Velcade and low-dose dexamethasone. Velcade is marketed by Takeda Pharmaceutical Company Ltd..

  8. Show article details.

    BRIEF-Karyopharm Announces Phase 3 Boston Study Meets Primary Endpoint

    Reuters – 7:18 AM ET 03/02/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM ANNOUNCES PHASE 3 BOSTON STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT INCREASE IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA FOLLOWING ONE TO THREE PRIOR LINES OF THERAPY. * Karyopharm Therapeutics Inc (KPTI) - REGULATORY SUBMISSION PLANNED IN 2Q 2020; DATA TO BE SUBMITTED FOR PRESENTATION AT UPCOMING MEDICAL MEETINGS.

  9. Show article details.

    Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy

    GlobeNewswire – 7:00 AM ET 03/02/2020

    − Combination of Once-Weekly XPOVIO®, Once-Weekly Velcade® plus Dexamethasone Results in Statistically Significant Reduction in the Risk of Disease Progression or Death Compared to Standard Twice-Weekly Velcade® plus Dexamethasone Regimen  − − 47% Increase in Median PFS on SVd versus Vd – − Regulatory Submission Planned in 2Q 2020; Data to be Submitted for Presentation at Upcoming...

  10. Show article details.

    Karyopharm Appoints Richard Paulson to its Board of Directors

    GlobeNewswire – 7:00 AM ET 02/28/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced the appointment of Richard Paulson to its Board of Directors.

  11. Show article details.

    U.S. Food and Drug Administration Accepts Karyopharm’s Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    GlobeNewswire – 8:00 AM ET 02/19/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application seeking accelerated approval for oral XPOVIO® tablets, the Company’s first-in-class, Selective Inhibitor of Nuclear Export compound, for the treatment of adult patients with relapsed or refractory di...

  12. Show article details.

    Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference

    GlobeNewswire – 7:00 AM ET 02/18/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 11:30 a.m. ET in NYC.

  13. Show article details.

    BRIEF-Karyopharm Therapeutics Posts Q4 Loss Per Share Of $0.76

    Reuters – 7:21 AM ET 02/13/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND HIGHLIGHTS RECENT COMPANY PROGRESS. * Q4 LOSS PER SHARE $0.76. * Q4 EARNINGS PER SHARE ESTIMATE $-0.67 -- REFINITIV IBES DATA. * QTRLY TOTAL REVENUES $18.1 MILLION VERSUS $206,000 Source text for Eikon: Further company coverage:

  14. Show article details.

    Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

    GlobeNewswire – 7:00 AM ET 02/13/2020

    -- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 -- -- XPOVIO Prescription Demand Increased by 65% in Fourth Quarter 2019 Compared to Third Quarter 2019 -- -- sNDA for Selinexor in DLBCL Submitted to FDA -- -- Phase 3 BOSTON Top-Line Data Expected Before End of April 2020 -- -- Conference Call Scheduled for Today at 8:30 a.m. ET -- ...

  15. Show article details.

    BRIEF-Karyopharm And Promedico Enter Agreement To Commercialize Xpovio (Selinexor) In Israel

    Reuters – 7:35 AM ET 02/11/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM AND PROMEDICO, A MEMBER OF THE NEOPHARM GROUP, ENTER INTO AN EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE XPOVIO® IN ISRAEL. * KARYOPHARM THERAPEUTICS (KPTI) - RETAINED EXCLUSIVE PRODUCTION RIGHTS AND WILL SUPPLY FINISHED PRODUCT FOR COMMERCIAL USE IN COVERED TERRITORY.

  16. Show article details.

    Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel

    GlobeNewswire – 7:00 AM ET 02/11/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement for the commercialization of XPOVIO®, Karyopharm’s lead SINE compound, in Israel and the Palestinian Authority.

  17. Show article details.

    Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

    GlobeNewswire – 7:00 AM ET 02/06/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 13, 2020. To access the conference call, please dial  437-4406 or  756-4292 at least 10 minutes prior to the start time and refer to conference ID 4367549.

  18. Show article details.

    Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    GlobeNewswire – 4:05 PM ET 02/03/2020

    Karyopharm Therapeutics Inc. (KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 87,000 shares of Karyopharm’s common stock to sixteen newly-hired employees, with a grant date of January 31, 2020.

  19. Karyopharm Therapeutics downgraded to neutral from outperform at Wedbush

    MarketWatch – 8:18 AM ET 01/17/2020
  20. Show article details.

    BRIEF-Karyopharm Announces Preliminary Unaudited Q4 And FY2019 Product Sales For Xpovio

    Reuters – 7:19 AM ET 01/13/2020

    Karyopharm Therapeutics Inc (KPTI): * KARYOPHARM ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2019 PRODUCT SALES FOR XPOVIO® AND PROVIDES COMMERCIAL UPDATE. * KARYOPHARM THERAPEUTICS (KPTI) - EXPECTS NET PRODUCT SALES OF XPOVIO TO BE BETWEEN $17 AND $18 MILLION DURING Q4 2019 Source text for Eikon: Further company coverage:

Page:

Today's and Upcoming Events

  • May
    07

    KPTI to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    13

    KPTI announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.